Literature DB >> 3156964

EMD 23,448: effects of a putative dopamine autoreceptor agonist in chorea.

R P Newman, C A Tamminga, T N Chase, P A LeWitt.   

Abstract

A novel dopamine agonist, which stimulates presynaptic dopamine receptors in the experimental animal, was administered acutely to four patients with chorea. Abnormal involuntary movements worsened, plasma prolactin levels fell, and plasma growth hormone concentrations increased in all patients tested. These effects resemble those associated with a postsynaptic rather than presynaptic dopamine agonist, and thus raise some question about the ability of conventional dopaminomimetic screens to predict clinical activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156964     DOI: 10.1007/bf01253057

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  14 in total

1.  The occurrence, distribution and physiological role of catecholamines in the nervous system.

Authors:  A CARLSSON
Journal:  Pharmacol Rev       Date:  1959-06       Impact factor: 25.468

2.  Characterization of brain dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; E D Bird; E Spokes; H I Yamamura
Journal:  Commun Psychopharmacol       Date:  1978

Review 3.  The pharmacology of choreatic movement disorders.

Authors:  H L Klawans; W J Weiner
Journal:  Prog Neurobiol       Date:  1976       Impact factor: 11.685

4.  Antipsychotic drugs, neurotransmitters, and schizophrenia.

Authors:  A Carlsson
Journal:  Am J Psychiatry       Date:  1978-02       Impact factor: 18.112

5.  Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity.

Authors:  W Kehr; A Carlsson; M Lindqvist; T Magnusson; C Atack
Journal:  J Pharm Pharmacol       Date:  1972-09       Impact factor: 3.765

6.  Apomorphine in Huntington's chorea: clinical observations and theoretical considerations.

Authors:  E S Tolosa; S B Sparber
Journal:  Life Sci       Date:  1974-10-01       Impact factor: 5.037

Review 7.  Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia.

Authors:  R J Baldessarini; D Tarsy
Journal:  Int Rev Neurobiol       Date:  1979       Impact factor: 3.230

8.  Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain.

Authors:  C A Seyfried; K Fuxe; H P Wolf; L F Agnati
Journal:  Acta Physiol Scand       Date:  1982-12

9.  Cholinergic influences in tardive dyskinesia.

Authors:  C A Tamminga; R C Smith; S E Ericksen; S Chang; J M Davis
Journal:  Am J Psychiatry       Date:  1977-07       Impact factor: 18.112

10.  Dopamine D-1 and D-2 receptors in Huntington's disease.

Authors:  A Cross; M Rossor
Journal:  Eur J Pharmacol       Date:  1983-03-25       Impact factor: 4.432

View more
  1 in total

1.  A novel rhesus macaque model of Huntington's disease recapitulates key neuropathological changes along with motor and cognitive decline.

Authors:  Alison R Weiss; William A Liguore; Kristin Brandon; Xiaojie Wang; Zheng Liu; Jacqueline S Domire; Dana Button; Sathya Srinivasan; Christopher D Kroenke; Jodi L McBride
Journal:  Elife       Date:  2022-10-07       Impact factor: 8.713

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.